Influence Of Incomplete Revascularization on Long-Term Outcomes After Primary Percutaneous Coronary Intervention (PPCI)
NCT ID: NCT04332250
Last Updated: 2020-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3200 participants
OBSERVATIONAL
2016-01-01
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Indices in Patients Undergoing Primary PCI and Its Prognostic Value
NCT04290949
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion
NCT06542653
Prognostic Implications of Physiologic Investigation After Revascularization With Stent
NCT04684043
Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization
NCT07197242
Outcomes of Isolated LCx Occlusion
NCT06750328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Group I: Complete revascularization was achieved by PPCI.
2. Group II: Complete revascularization was not achieved by PPCI.
* In hospital outcomes: All the patients will be reviewed for during hospital admission to record major acute cardiac events (MACE). Only the most serious event of major adverse cardiac events will be used to calculate the cumulative major adverse cardiac events per patient according to the following sequence: (death \> heart failure \> recurrent non-fatal MI \> serious secondary arrhythmia necessitating DC shock\> recurrent or refractory angina. MACE will be reported according to the standard definitions.(Tsai IT, et al.,2017)
* Long-term follow-up: The patients will be followed by telephone interviews for all-cause mortality, re-hospitalization by ACS, re-hospitalization by heart failure, planned and unplanned PCI or CABG. Long-term MACE will include: all-cause mortality, re-hospitalization by ACS, re-hospitalization by heart failure, unplanned revascularization. Patients who undergo planned revascularization later on after discharge will be followed till the date of revascularization for actual events and will be censored in Kaplan Meier Survival analysis. These patients will be included in a third group of staged late complete revascularization to be followed for the long-term MACE events starting from the planned revascularization procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Exclusion Criteria
* Patients with previous coronary artery bypass grafting (CABG).
* Patients presenting with cardiogenic shock, cardiac arrest or pulmonary edema.
* Mechanical complications of MI; namely VSD, wall rupture, mitral regurgitation secondary to papillary muscle or chordal rupture.
* Patients with unsuccessful PPCI with a final TIMI flow ≤ I in infarct related artery.
* Patients with a significant co-morbidity reducing life expectancy to \<1 year as patients with advanced liver diseases, cerebrovascular diseases, malignancy and chronic lung diseases that could affect patient prognosis
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amany Edward Ramzy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amany Edward Ramzy
Principle investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Amany Edward Ramzy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.